Company intelligence / Profile preview
Changchun Institute of Biological Products Co., Ltd.
- Ownership
- Private
- Employees
- ~900
- Development stage
- Other
Overview
CCIBP has a long track record as one of China’s leading vaccine manufacturers. Its quadrivalent influenza vaccine has been marketed for over two decades with more than 90 million doses sold and WHO prequalification achieved. The company also produces approved hepatitis A and rabies vaccines. It continues to develop new prophylactic vaccines targeting emerging infectious diseases such as tick-borne encephalitis and viral hemorrhagic fevers. Clinical trials are ongoing for next-generation influenza formulations and other indications.
- Therapeutic areas
- ImmunologyInfectious Diseases
- Modalities
- Prophylactic vaccinesinactivated vaccineslive attenuated vaccinesbiosimilarsinterferons
- Industry
- Biotech
Drug pipeline
9 assets8 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Changchun Institute of Biological Products Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Changchun Institute of Biological Products Co., Ltd..